Current Factor IX (FIX) products display a half-life (t 1/2 ) of approximately 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in hemophilia B patients. This open-label, dose-escalation trial in previously treated adult subjects with hemophilia B examined the safety and pharmacokinetics (PK) of rFIXFc. rFIXFc is a recombinant fusion protein composed of FIX and the Fc domain of human IgG 1 , to extend circulating time. Fourteen subjects received a single dose of rFIXFc: one subject each received 1, 5, 12.5, or 25 IU/kg, and 5 subjects each received 50 or 100 IU/kg. rFIXFc was well tolerated and most AEs were mild or moderate in intensity. No inhibitors were detected in any subject. Dose-proportional increases in rFIXFc activity and antigen exposure were observed. Utilizing baseline subtraction, mean activity terminal t 1/2 and mean residence time for rFIXFc were 56.7 and 71.8 hours, respectively. This is approximately 3-fold longer than that reported for current rFIX products. The incremental recovery of rFIXFc was 0.93 IU/dL per IU/kg, similar to plasma-derived FIX. These results show that rFIXFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia B. The trial was registered at www.clinicaltrials.gov as NCT00716716.
Introduction
Hereditary deficiency of clotting factor IX (FIX), hemophilia B, results in spontaneous or traumatic bleeding into the joints, soft tissues, and body cavities. 1 When not treated adequately with FIX replacement therapy, bleeding results in disability and increased risk of death. 2 Early individualized prophylactic treatment can improve outcomes by reducing the incidence of hemarthroses and subsequent arthropathy. 3, 4, 5 FIX replacement therapy has been utilized for approximately 40 years, initially purified from plasma (pdFIX), and more recently manufactured as a recombinant human FIX (rFIX). Both pdFIX and rFIX achieve effective and safe hemostasis in the prophylactic and surgical settings. 1 The current prophylaxis regimen is given two to three times weekly by intravenous infusion. The frequency is determined by the half-life (t 1/2 ) (approximately 18 hours) and recovery of rFIX.
The requirement for frequent dosing can be a deterrent for adhering to a prophylactic regimen due to concerns about venous access and associated complications, such as thrombosis and infection. 6, 7 Thus, extending rFIX t 1/2 and prolonging its protective hemostatic effect [8] [9] [10] may reduce the number of injections needed to achieve effective hemostasis using a prophylaxis regimen or to control breakthrough bleeds in on-demand therapy.
rFIXFc is a recombinant monomeric fusion protein composed of a single molecule of FIX covalently fused to the human IgG1 Fc domain, demonstrating increased circulating t 1/2 and bleeding control in several species. 10 Activity was achieved with no cleavable linker between FIX and Fc, in contrast to other fusion proteins. 9 The Fc domain permits binding to the neonatal Fc receptor (FcRn), expressed widely within endothelial cells and other cell types, and also represents a natural molecule with no known inherent toxicity. 10 FcRn is constitutively expressed
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From throughout life and is responsible for protecting IgG 1 and Fc-fusion proteins from lysosomal degradation. 11, 12 Fc-fusion proteins taken up by pinocytosis and/or endocytosis interact with FcRn, resident within endosomes, which, in turn, direct the Fc-fusion proteins back to the plasma membrane, reintroducing them into circulation in a pH-dependent manner. 13 This recycling approach has been used to extend the t 1/2 of Fc fusion-based drugs used clinically (e.g.,
etanercept, romiplostim) and in development. 14, 15 In mice, rats, dogs, and non-human primates, the t 1/2 of rFIXFc is 3 to 5-fold longer than rFIX, 10 indicating for the first time that FIX is cleared, at least in part via lysosomal degradation, and that FIX t 1/2 can be extended via redirection to a natural protective pathway mediated by FcRn.
This is a first-in-human clinical study which investigates the safety and pharmacokinetics (PK) of a long-acting FIX Fc-fusion protein in hemophilia B patients.
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Methods

Study design
This study was performed in accordance with the US CFR and ICH Guidelines on Good Clinical
Practices. Prior to any testing, approval from participating Institutional Review Boards and written informed consents from all subjects were obtained in accordance with the Declaration of Helsinki.
This was a Phase 1/2a, open-label, multicenter, dose-escalation study of single-dose rFIXFc in previously treated subjects with severe hemophilia B (ClinicalTrials.gov identifier NCT00716716). The primary objective was to assess the safety of rFIXFc over 30 days and the secondary objective was to estimate the PK parameters of rFIXFc at doses ranging from 12.5 to 100 IU/kg. Subject eligibility was determined and one dose of rFIXFc was infused intravenously over approximately 10 minutes at 6 sequential dose levels: 1, 5, 12.5, 25, 50, and 100 IU/kg. Plasma samples to measure FIX activity at doses of 12.5 IU/kg and above were taken at baseline preinfusion, immediately post-infusion, and 0.25, 1, 3, 6, 9, 24, 48, 72, 96, 120, 168 , and 240 hours (10 days) post-infusion. At the 100 IU/kg dose, samples were also taken at 12 and 14 days.
Subjects
Male subjects at least 18 years of age with severe (defined as ≤ 2 IU/dL FIX:C) hemophilia B and at least 150 prior documented exposure days to other FIX products were included. Individuals with a history of inhibitors, allergic or anaphylactoid reactions associated with FIX or intravenous immunoglobulin, concurrent autoimmune disease, coagulation disorder other than hemophilia B, or who were taking medications that could affect hemostasis were excluded. For
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Treatment product
rFIXFc was produced in HEK293 cells extensively tested for stability, sterility, and viral contamination to ensure safety. The purified drug product is composed of a monomeric rFIX covalently fused through its carboxy terminus to the N-terminus of a Fc monomer, which forms a disulfide bond with a second Fc monomer during synthesis and secretion from the cells. 10, 15 rFIXFc was supplied as a frozen (-70ºC) liquid containing 1000 IU of rFIXFc per 5 mL (200 IU/mL) of formulation buffer (10 mM sodium phosphate buffer [pH 7.0], 145 mM sodium chloride, and 0.1% polysorbate 20).
Outcome measures
Safety was evaluated by physical examination, vital signs, ECG, development of AEs, neutralizing and total binding antibody development, and laboratory changes over time.
Secondary endpoints included estimated PK parameters. Laboratory assessments included viral status, levels of D-dimer and thrombin-antithrombin (TAT) complex, hematology, serum chemistry, and urinalysis. FIX antigen and rFIXFc concentrations in plasma were measured by ELISAs specific for FIX or rFIXFc (lower limit of quantification [LLOQ] of 10 and 16 ng/mL, respectively). FIX activity was determined by the one-stage (aPTT) clotting assay using Normal Reference Plasma as a calibrator (LLOQ 1 IU/dL), which has a potency assigned against the WHO 3rd International Standard for Factors II, VII, IX and X. FIX inhibitor was measured by Nijmegen-modified Bethesda assay (LLOQ 0.6 BU/mL), and the anti-FIXFc antibodies were
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Pharmacokinetic analyses
FIX activity PK parameters were determined for the 25, 50, and 100 IU/kg dose groups (n = 11).
A baseline subtraction method was used to account for endogenous FIX and incomplete elimination of the previous prophylactic dose when calculating the rFIXFc activity-versus-time profile. Baseline was defined based on the subjects' pre-dose FIX antigen levels and the lowest FIX activity (at screening, pre-dose, or post-dose). Six of 11 subjects had baseline activity ≤ 1%, and the remaining 5 subjects had baseline activities of 2%. If residual drug was present pre-dose, it was decayed using ordinary first-order elimination with a t 1/2 based on that reported for BeneFIX (18 hours). 16 The FIX activity-versus-time data were computer-fitted to a two-compartment model in WinNonlin, version 5.2.1 (Pharsight Inc., Mountain View, CA) for calculation of PK parameters including maximum activity (Cmax), t 1/2 , clearance (CL), volume of distribution at steady-state (V ss ), area under the curve (time zero extrapolated to infinity) (AUC INF ), mean residence time (MRT), and incremental recovery (K). In addition, plasma FIX activity above subject's baseline at 168 hours (7 days) post dose, and time after dosing when FIX activity declined to 3 and 1 IU/dL above the subject's baseline level were also estimated. Actual sampling times, doses, and infusion durations were used in all calculations.
Similar PK analyses were also applied to the rFIXFc antigen concentration-versus-time data.
Since the sensitivity of the rFIXFc antigen ELISA was approximately 10-fold greater than that of the FIX one-stage (aPTT) clotting assay, antigen data from all subjects in the dose groups of 12.5
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From to 100 IU/kg up to 336 hours post dosing were included in the PK analysis. For derivation of rFIXFc antigen PK parameters, doses were converted to "mg/kg" based on rFIXFc specific activity.
The assay was specific for rFIXFc antigen, thus, the pre-treatment baseline was below the limit of detection, irrespective of whether the subjects had circulating dysfunctional endogenous FIX antigen or residual exogenous FIX from their last infusion.
To construct the activity-time profiles at steady state following different dosing regimens, Monte Carlo simulation was conducted using the population PK model of rFIXFc. The mean estimates of model parameters (CL, volume of distribution, inter-compartmental clearance, and volume of the second compartment) in the tested population, the inter-individual variance, and the residual variability were adopted from this Phase1/2a study. One thousand subjects were simulated per dosing regimen for a total of 5 dosing cycles for each subject. The body weight (BW) was generated according to the published method, 17 ie, based on a power equation of Z=BW -0.5
. The median BW in 1000 subjects was assumed to be 75 kg. Based on the simulated activity-time profiles, the mean and 95% CI of the model-simulated drug activity-time profiles of the 1000 subjects was constructed graphically for different dosing regimens.
Statistical analyses
Summary descriptive statistics were presented for all safety and PK parameters by dose level.
The correlations between the K value, CL, and V ss of rFIXFc activity with body weight, age, and endogenous FIX antigen levels were determined by linear regression with associated R 2 and p value, using GraphPad Prism version 5 (La Jolla, CA).
Results
Subject disposition
The study enrolled 15 subjects; 14 received an infusion of rFIXFc (Table 1) . One subject failed to return for study drug infusion and was withdrawn from the study. One subject each received 1, 5, 12.5, or 25 IU/kg, and 5 subjects each received either 50 or 100 IU/kg. All 14 subjects were included in the safety analysis; 12 subjects, who received 12.5 to 100 IU/kg doses of rFIXFc, were included in the PK analyses. The activity PK results for one subject (12.5 IU/kg) were excluded due to insufficient evaluable data to estimate the elimination phase. There were no clinically relevant differences among treatment groups. Subjects with a variety of hemophilia B genotypes, such as stop codon/nonsense and missense mutations, were included (Table 2) .
Several subjects had near absence of FIX antigen which correlated with markedly reduced FIX activity, while others with missense genotypes had more antigen than activity, indicating a dysfunctional circulating protein. The pre-treatment FIX activity in 2 subjects exceeded 2 IU/dL, likely due to an incomplete washout from their last infusion of FIX concentrate based on historical testing and disease phenotype.
Safety
A total of 16 AEs were reported by 7 subjects; AEs were distributed evenly across treatment groups (Table/Supplement). Most AEs were mild or moderate; the 2 treatment-related AEs included dysgeusia and headache, which occurred in one subject in the 50 IU/kg group. Two subjects experienced serious AEs that required hospitalization (abdominal adhesions and depression); neither was considered related to the study drug. No clinically relevant changes occurred in laboratory values, QT interval, or vital signs. No allergic reactions were detected. All plasma samples tested negative for FIX inhibitors and anti-rFIXFc antibodies.
Six subjects experienced bleeding episodes between 9 and 28 days post-dose during the study, when infused rFIXFc had been washed out. There were no reports of thrombosis during the study. In laboratory testing of thrombogenic markers, two subjects experienced sporadic, variable increases in TAT complex (5.8-43.1 ng/mL) during frequent blood draws over the first 24 to 48 hours; increases were not correlated with FIX activity levels. The maximal TAT elevations were 4 and 8-fold above the upper limit of normal, and were not correlated with D dimer levels which remained normal, nor with consistent patterns post-dosing in both patients.
The short t 1/2 of TAT (15 minutes) suggested slight coagulation activation possibly due to documented difficult phlebotomies, as D-dimer formation (24 hour t 1/2 ) remained negative.
Pharmacokinetics
A dose-proportional increase in FIX activity was observed based on C max occurring immediately after infusion and AUC INF (Table 3) . FIX activity exhibited biexponential decay following infusion of rFIXFc, and was characterized by a short distribution (alpha) phase followed by a log-linear elimination (beta) phase ( Figure 1A) . The mean distribution t 1/2 (t 1/2α ) was variable for individual subjects (mean of 3.31 and 10.3 hours for the two higher dose groups) ( Table 3 ). The mean elimination t 1/2 (t 1/2β ) was dose-independent over the therapeutic dose range tested, ie, 53.5 hours, 57.6 ± 8.27 hours, and 56.5 ± 14.1 hours at 25 IU/kg, 50 IU/kg, and 100 IU/kg, respectively. The mean t 1/2β reported for rFIX (BeneFIX) is 19.3 ± 4.97 hours (range 11.1 -36.4 hours). 16 The average time to 1% (1 IU/dL) above baseline, a surrogate assessment of rFIXFc efficacy, showed a dose-proportional increase. It was 7.34, 10.1 ± 1.58, and 12.3 ± 2.49 days for
For personal use only. on May 29, 2017. by guest www.bloodjournal.org From doses of 25, 50, and 100 IU/kg, respectively. The average time to 3% above baseline was 3.81, 6 .28 ± 1.11, and 8.53 ± 1.58 days following doses of 25, 50, and 100 IU/kg, respectively. At 168 hours (1 week) post dose, the plasma FIX activity was sustained at an average of 1.11 IU/dL, 2.47 ± 0. 911 IU/dL, and 4.65 ± 1.73 IU/dL above baseline for the 25, 50, and 100 IU/kg dose groups, respectively. MRT, CL, and V ss were all dose independent. The mean MRT for all dose groups was 71.9 ± 9.66 hours (range 53.2 -85.9 hours), while the corresponding value reported for rFIX was 26.0 ± 6.07 hours (range 15.8 -46.1 hours). The mean CL of rFIXFc was 3.18 mL/hours/kg, while the reported value for rFIX was 8.40 ± 2.01 mL/hr/kg and the mean Vss of rFIXFc was 227 ± 57.1 mL/kg (range 162 -296 mL/kg). 16 Furthermore, each 1 IU/kg of infused rFIXFc raised plasma FIX activity by 0.930 ± 0.179 IU/dL on average (Table 3) 
16
Plasma rFIXFc antigen levels were measured by a rFIXFc-specific ELISA, and the concentration-versus-time curves are shown in Figure 1B . Findings from rFIXFc activity PK were corroborated by rFIXFc antigen PK (Table 4) . Plasma rFIXFc concentrations also declined biexponentially following infusion, with the C max detected immediately after dosing. The plasma rFIXFc activity, as measured by the one-stage (aPTT) clotting assay, correlated well with rFIXFc antigen by ELISA in individual subjects (data not shown) and all subjects as a group (R 2 =0.946, p<0.0001) ( Figure 1C) . However, the mean dose-independent t 1/2α (13.2 ± 3.95 hours), t 1/2β (101 ± 20.9 hours), and MRT (110 ± 18.5 hours) of rFIXFc antigen were longer than those determined by plasma FIX activity measurements (Table 4) .
For
Discussion
Studies have demonstrated clear medical benefits with early individualized prophylactic therapy in hemophilia.
18-20 To achieve wider acceptance, prophylaxis therapy needs to be effective, convenient, simple, and safe. Introduction of rFIXFc replacement therapy with a prolonged t 1/2 may represent an important step towards achieving these goals. 21 Moreover, a FIX product with an extended half-life compared to currently available products may have a greater impact in the treatment of episodic bleeds through a potential reduction in the number of follow-up treatments needed to control a bleed. A long-lasting FIX product may also influence defective wound healing, as has been described for hemophilia B.
22
rFIXFc was not associated with inhibitor formation in any subject, all of whom had prior exposure to FIX products. Moreover, there was no evidence of allergic reactions or thrombogenicity as reported previously for rFIX. 23 Levels of activated FIX (FIXa) are extremely low in rFIXFc, less than 10% of the levels reported for currently marketed rFIX and 5% of the levels reported for pdFIX products. 10 Results provide insight into the PK of rFIXFc in patients with hemophilia B. C max was reached immediately after infusion, suggesting a rapid onset of action similar to rFIX. The incremental recovery observed for rFIXFc may represent an improvement compared with that reported for rFIX in 56 previously treated subjects. 16 The improved recovery may be attributable to differences in posttranslational modification(s) from the HEK cell line, or the Fc moiety. In this study, the incremental recovery of rFIXFc is weakly correlated with body weight (R 16, 23 Furthermore, the ranges for rFIXFc and rFIX do not overlap, and are consistent with the extended PK for rFIXFc observed in 4 different animal species. 10 The t 1/2α distribution phase averages approximately 7 hours in rFIXFc patients, considerably longer than historical values for rFIX (2 to 3 hours). Similarly, the mean CL of rFIXFc activity is approximately 2.6-fold less than that reported for rFIX. 16 Although the same trend in improvement was observed in the rFIXFc antigen PK, both the t 1/2α
and t 1/2β of rFIXFc antigen were longer than those derived from FIX activity. This discrepancy could in part be attributed to the markedly more sensitive antigen assay that enabled inclusion of antigen values detectable at much later time points (up to 336 hours) in the calculation of the t 1/2β . If the terminal antigen half-life is terminated at the same time points as the lowest reliably detected activity, the half-lives are similar at 73.0 ± 19.7 hours. Further studies in larger number of subjects will be important to assess rFIXFc activity versus antigen levels over time.
Data from PK analyses provide a means of optimizing individualized prophylactic treatment to achieve target trough levels above 1% (1 IU/dL) of baseline, and reduce peak/trough variation. 27, 28 In comparison with the recommended dose regimen of 25 to 40 IU/kg of FIX twice weekly, the rFIXFc activity PK modeling results from this study suggest that once weekly dosing of rFIXFc at 20 IU/kg, or every 10 days at 40 IU/kg, or every 2 weeks at 100 IU/kg is sufficient to maintain a mean trough of 1% above baseline in the adult hemophilia B patient population ( Figure 2 ). These model-simulated estimates, however, must consider the heterogeneity of reported clinical breakthrough bleeding events relative to trough level of plasma FIX activity, 29, 30 in addition to the heterogeneity in individual subjects' PK parameters. Thus, prophylaxis dosing may require individual adjustment, as is often required now. http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html.
For Table 1 and intra-subject variability were adopted from this Phase1/2a study. Based on the simulated activity-time profiles, the mean and 95% CI of the activity-time profiles of the 1000 subjects was constructed graphically for different dosing regimens for a total of five dosing cycles when the steady state was achieved.
Tables and Figures
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